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Summary. Background: Chronic hyperglycemia is a major
contributor to in vivo platelet activation in diabetes mellitus.
Objectives:To evaluate the eﬀects of acarbose, an a-glucosidase
inhibitor, on platelet activation and its determinants in newly
diagnosed type 2 diabetic patients. Methods: Forty-eight
subjects (26 males, aged 61 ± 8 years) with early type 2
diabetes (baseline hemoglobin A1c £ 7% and no previous
hypoglycemic treatment) were randomly assigned to acarbose
up to 100 mg three times a day or placebo, and evaluated every
4 weeks for 20 weeks. The main outcome measures were
urinary 11-dehydro-thromboxane (TX)B2 (marker of in vivo
platelet activation) and 8-iso-prostaglandin (PG)F2a (marker of
in vivo lipid peroxidation) excretion rate, 2-h postprandial
plasma glucose (PPG) after a test meal, and assessment of
glucose ﬂuctuations by mean amplitude of glycemic excursions
(MAGE).Results:Baselinemeasurements revealedbiochemical
evidence of enhanced lipid peroxidation and platelet activation.
As compared with the placebo group, patients treated with
acarbose had statistically signiﬁcant reductions in urinary 11-
dehydro-TXB2 and 8-iso-PGF2a excretion rate as early as after
8 weeks and at each subsequent time point (between-group
P < 0.0001 at 12, 16 and 20 weeks), following earlier decreases
in PPG and MAGE. Multiple regression analyses in the
acarbose group revealed that PPG was the only signiﬁcant
predictor of 11-dehydro-TXB2 urinary excretion rate
(b = 0.39, P = 0.002) and MAGE the only predictor of 8-
iso-PGF2a urinary excretion rate (b = 0.42, P = 0.001).
Conclusions: Postprandial hyperglycemia is associated with
enhanced lipid peroxidation and platelet activation in early
type 2 diabetes. A moderate decrease in PPG achieved with
acarbose causes time-dependent downregulation of these
phenomena, suggesting a causal link between early metabolic
abnormalities and platelet activation in this setting.
Keywords: acarbose, platelet activation, postprandial hypergly-
cemia, type 2 diabetes mellitus.
Introduction
Diabetes mellitus is associated with accelerated atherogenesis,
resulting in premature ischemic manifestations of coronary,
cerebrovascular and peripheral arterial disease [1]. Platelet
activation has a pivotal role in the initiation and progression of
atherothrombosis [2]. Abnormalities in the aggregation of
diabetic platelets ex vivo were described by several groups [3],
and chronic hyperglycemia was identiﬁed as a major determi-
nant of in vivo platelet activation in diabetic patients [4].
We previously demonstrated enhanced thromboxane (TX)
biosynthesis in type 2 diabetes mellitus and provided evidence
that it is derived predominantly from platelets [4,5]. We also
reported increased peroxidation of arachidonic acid to form
biologically active F2-isoprostanes, which may provide an
important biochemical link between impaired glycemic control,
enhanced oxidant stress and persistent platelet activation in this
setting [6]. Tight metabolic control achieved by intensive insulin
treatment, as well as metabolic improvement obtained by
frequent reassessment of sulfonylurea therapy, reduced iso-
prostane formation and TX biosynthesis, as reﬂected by the
urinary excretion of the TX metabolite 11-dehydro-TXB2
[4,6,7]. However, prior studies evaluating lipid peroxidation
and platelet activation in diabetesmellitus have been performed
in patients at an advanced stage of the natural history of the
disease, when the relative contribution of metabolic abnormal-
ities with regard to accelerated atherogenesis to triggering
platelet activation cannot be evaluated separately.
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Postprandial hyperglycemia, an early metabolic abnormality
often preceding the clinical diagnosis of diabetes, is an
independent risk factor for cardiovascular disease in type 2
diabetes [8]. The mechanism(s) by which glucose ﬂuctuations
during the postprandial period exert their deleterious effects
may include enhanced oxidative stress and endothelial dys-
function, both of which contribute to platelet activation [3,9].
Treating patients with impaired glucose tolerance with acar-
bose, an a-glucosidase inhibitor that reduces postprandial
hyperglycemia, prevents acute endothelial dysfunction [10] and
may lower the risk of atherothrombotic events [11].
In the present study, we set out to evaluate biochemical
indices of platelet activation and lipid peroxidation in patients
with early type 2 diabetes mellitus and adequate metabolic
control, naı¨ve to hypoglycemic drugs, and with no evidence of
microvascular or macrovascular complications. Moreover, in
order to test the hypothesis that postprandial hyperglycemia is
an important determinant of platelet activation in the early
stage of diabetes, we performed a randomized, double-blind,
placebo-controlled, multicenter study evaluating the effects of
acarbose on platelet activation and its potential determinants in
this setting.
Materials and methods
Setting and participants
We studied subjects with type 2 diabetes, diagnosed according
to the American Diabetes Association criteria [12], in an early
stage as deﬁned by a known disease duration £ 6 months,
presenting at the time of recruitment with hemoglobin (Hb)A1c
values £ 7% in the absence of any treatment affecting glycemic
control. Fifty-four caucasian subjects (30males and 24 females,
aged 61.4 ± 7.6 years) were recruited (from May 2005
through August 2007) at the Diabetes Clinics of the Univer-
sities of Chieti, Palermo, Pisa and Rome Tor Vergata. Of
these, 48 patients (26 males and 22 females, aged
60.7 ± 8.3 years) completed the randomized study and con-
stitute the subject of this report.
During the screening evaluation, subjects were excluded
from participating in the study if they presented any of the
following: cigarette smoking; evidence of clinically signiﬁcant
hepatic, renal, cardiac or pulmonary insufﬁciency; history of
malignant neoplasms (diagnosed and treated within the last
5 years); type 1 diabetes mellitus; microvascular complications
(nephropathy, detected by the presence of persistent microal-
buminuria between 30 and 300 mg per 24 h, in at least two of
three consecutive 24-h urine collections; retinopathy, based on
fundus oculi examination); macrovascular complications (neg-
ative clinical history of stroke, ischemic heart disease or
peripheral arterial occlusive disease; negative electrocardio-
gram and arterial Doppler scanning); pregnancy or lactation;
history of malabsorption; or regular (daily) consumption of
alcohol. Patients requiring chronic non-steroidal anti-inﬂam-
matory drug therapy or low-dose aspirin were also excluded.
Throughout the study, the only admitted analgesic was
paracetamol (up to 500 mg d)1). All patients with documented
gastrointestinal disease and those taking medications likely to
alter gut motility or absorption were also excluded. Patients
with arterial hypertension or hypercholesterolemia were
included if well controlled with stable drug therapy.
Study design
The study included a 3-week baseline period and a 20-week
double-blind randomized treatment period. During the base-
line period, patients were not treated with any drugs that could
interfere with glucose metabolism.
Peripheral venous blood (at 9 a.m., after 12 h of fasting, and
2 h after a standard meal) and overnight urine samples were
collected on the ﬁrst and third weeks. Urine samples were
additioned with the antioxidant 4-hydroxy-Tempo (1 mmol
L)1) (Sigma Chemical Co., St Louis, MO, USA) and stored at
) 20 C until extraction.
At the end of the baseline period, patients were randomly
assigned to receive acarbose (up to 100 mg three times daily) or
placebo in addition to dietary counseling. On the basis of the
order of inclusion in the study, subjects were assigned a
consecutive random number, and then allocated to one of the
two treatment groups according to a permuted-block, 1 : 1
randomization list generated by the trial statistician with blocks
of six participants, in which medication numbers 1–54 corre-
sponded to either acarbose or placebo. These numbers were
stored in opaque envelopes and opened by the enrolling clinic
staff at the time of enrollment; opening the envelope consti-
tuted admission to the trial. Patients and all investigators were
blind to the treatment allocation.
Acarbose was titrated over a period of 4 weeks, according to
the following schedule: 50 mg once daily for the ﬁrst 7 days (at
dinner time); 50 mg twice daily (lunch and dinner) for the
following 7 days; 50 mg three times daily (at breakfast, lunch
and dinner) for another week; and ﬁnally, 100 mg three times
daily. Down-titration to 50 mg three times daily for those who
could not tolerate 100 mg three times daily was allowed in
order to minimize the rate of drop-out.
During the double-blind treatment period, each subject
received the randomized treatment every day with the ﬁrst bite
of each meal. Moreover, during this period, blood (at 9 a.m.,
after 12 h of fasting, and 2 h after a standard meal) and
overnight urine samples were collected on the fourth, eighth,
12th, 16th and 20th weeks of treatment.
The standard meal consisted of measured portions of food
containing 70 g of carbohydrates: 250 g of skimmed milk
(about 234 kJ), ﬁve slices of toast (about 652 kJ), and two
teaspoons of jam (about 292 kJ).
Patients were taught to self-monitor by ﬁngerprick, and a
glucometer was provided at the time of randomization.
Subjects were asked to monitor their blood glucose at home
once a week with nine determinations (before, 1 h after and 2 h
after breakfast, lunch and dinner).
At randomization, patients were instructed to follow a low-
fat and low-caloric diet () 20% of estimated daily energy
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expenditure), and were encouraged to exercise regularly; these
instructions were reinforced at each visit. Drug compliance was
veriﬁed by pill counts.
Written informed consent was obtained from all participat-
ing subjects. The protocol was approved by the local Ethics
Committees, and the study was performed in accordance with
the principles of the Declaration of Helsinki, as revised in 2004.
Biochemical measurements
Blood glucose was measured by the glucose-oxidase method,
and plasma insulin wasmeasured by radioimmunoassay (Coat-
A-Count Insulin kit; Diagnostic Products Corporation, Los
Angeles, CA, USA). Incremental area under the curve was
calculated using the trapezoidal rule after subtraction of the
fasting glucose value.
Calculation of the mean amplitude of glycemic excursions
(MAGE) was performed by measuring the arithmetic mean of
the difference between consecutive peaks and nadirs, provided
that the difference was greater than the standard deviation
(SD) around the mean glucose values, using the nine-point
glucose proﬁles obtained weekly during the double-blind
treatment period. Homeostasis model assessment of insulin
resistance (HOMA-IR) was performed as described by Mat-
thews et al. [13].
Total cholesterol, triglyceride and high-density lipoprotein
cholesterol concentrations were measured as previously
described [14]. Low-density lipoprotein cholesterol was calcu-
lated using the Friedwald formula.
The urinary excretion rate of 8-iso-prostaglandin (PG)F2a, a
marker of lipid peroxidation in vivo, and 11-dehydro-TXB2
was measured by previously validated radioimmunoassay
techniques [15,16]. Mean urinary excretion rates of these
prostanoids in a non-diabetic population comparable for age
and gender have been reported previously [8-iso-PGF2a,
208 ± 92 pg mg)1 creatinine (mean ± SD); 11-dehydro-
TXB2, 415 ± 244 pg mg
)1 creatinine], using the same assay
[6]. Plasma CD40 ligand (CD40L) was determined by enzyme-
linked immunosorbent assay (ELISA) (R&D Systems, Min-
neapolis, MN, USA), according to recent recommendations
[17]. Venous blood samples were drawn into plasma vacuum
tubes containing one-tenth volume sodium citrate stock
solution at 0.129 mM by atraumatic and sterile antecubital
venipuncture at the study entry. To obtain platelet-poor
plasma, the citrated blood was centrifuged (ROTANTA/
TRC; Hettich, Tuttlingen, Germany) at 1500 · g for 15 min,
and to obtain platelet-free plasma a second centrifugation step
(Eppendorf, Milan, Italy) at 13 400 · g for 2 min was
performed. Plasma aliquots were stored at ) 80 C until they
were assayed for the determinations of interest. Samples were
coded before laboratory analysis. The technicians were
unaware of the patients characteristics at all times. Soluble
P-selectin (sP-selectin) levels were measured using a human sP-
selectin Immunoassay (R&D Systems), following the manu-
facturers instructions, as described previously [18]. We per-
formed duplicate measurements with 100-lL aliquots of
plasma diluted 20-fold into sample diluent included in the
ELISA reagent set and measured the absorbance at 450 nm
with a microplate reader (Spettra Max 190; Molecular
Devices, Sunnyvale, CA, USA). We read the sP-selectin
concentration from a calibration curve generated with SOFT -
MAX PRO software (version 4.3 LS; Molecular Devices). The
overall intra-assay and interassay coefﬁcients of variation
(CVs) were 2.4% and 5.2%, respectively, whereas the limit of
detection was 1.06 ng mL)1. Asymmetric dimethylarginine
(ADMA) levels were measured in plasma samples by a
commercially available enzyme-immunometric assay (DLD
Diagnostika, Hamburg, Germany). C-reactive protein (CRP)
plasma levels were measured by commercially available
high-sensitivity immunoassay (Dade Behring Laboratories,
Newark, DL, USA).
Statistical analysis
Sample size calculation was based on the primary endpoint
of the study, urinary 11-dehydro-TXB2 excretion rate at
20 weeks. It was estimated that 22 patients would be required
in each treatment group, for a two-tailed a of 0.05 and a power
of 80%, to detect a mean difference in 11-dehydro-TXB2
excretion rate of at least 40% between acarbose and placebo at
the end of the treatment period. Allowing for a 15% drop-out
rate, we estimated that 27 patients per group should be enrolled.
Given the actually measured baseline values of 11-dehydro-
TXB2 excretion rate (1595 ± 975 pg mg
)1 creatinine), and
with 48 subjects completing the treatment period, the study had
86% power to detect a mean absolute difference in excretion
rate of 650 pg mg)1 creatinine between the two groups.
Data from samples collected on the ﬁrst and third weeks
before randomization were averaged to obtain baseline values.
The intrasubject CV was the ratio of the SD to the mean
value of each variable in one subject over six repeated
measurements performed in the placebo group.
The Kolmogorov–Smirnov test and examination of residual
distribution were used to determine whether each variable had
a normal distribution.When necessary, log transformation was
used to normalize the data, or appropriate non-parametric tests
were used (Mann–Whitney U-test, Spearman correlation
coefﬁcient).
Comparisons of baseline data between the groups were
performed by chi-squared statistics, Fisher exact tests, unpaired
Students t-tests or Mann–Whitney U-tests.
For the primary analysis, we used a linear mixed-effects
model for repeatedmeasures over time, with 11-dehydro-TXB2
excretion rate as the dependent variable, week of visit, study
group and time-by-group interaction as ﬁxed effects, and
patients and error as random effects. Compound symmetry
was used to model the covariance structure within patients.
Within themixedmodel, we obtained least-squares estimates of
the treatment differences and standard errors, and estimated
95% conﬁdence intervals (CIs) and P-values for the two
prespeciﬁed intergroup contrasts (acarbose and placebo) for
change in 11-dehydro-TXB2 excretion rate value between
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baseline and weeks 4, 8, 12, 16 and 20, and over time within
each group.
For other continuous variables [fasting plasma glucose
(FPG), postprandial plasma glucose (PPG), HbA1c, MAGE,
HOMA-IR, body mass index (BMI), 8-iso-PGF2a, CD40L,
CRP,ADMA, P-selectin], we used the same procedure as in the
primary analysis.
Results for the repeated measure analysis are expressed as
(least square) means. Ninety-ﬁve per cent CIs were determined
on the basis of the difference between acarbose and placebo.
Data are represented as mean change from baseline (95% CI)
(Figs 2 and 3).
Associations between changes in FPG, PPG and HbA1c
values and changes in prostanoid measurements were assessed
by linear regression analysis. Multiple regression analyses with
stepwise variable selection were also performed, with urinary
8-iso-PGF2a or 11-dehydro-TXB2 excretion rate throughout
the study as the dependent variables.
Data are presented as mean ± SD or as median [interquar-
tile range (IQR)]. P-values lower than 0.05 were regarded as
statistically signiﬁcant. All tests were two-tailed, and analyses
were performed using the SPSS (v. 13.0; APSS, Chicago, IL,
USA), and STATA 9 (Stata Corp., College Station, TX, USA)
statistical packages.
Results
At baseline, BMI was 27.0 (24.7–30.2) kg m)2 [median (IQR)],
HOMA-IR was 2.81 (2.04–3.91) mg dL)1, FPG was
126.9 (120.6–138.8) mg dL)1, PPG was 164.5 (130.1–
194.6) mg dL)1, and HbA1c was 6.7% (6.3–7%) in the 54
diabetic patients. The urinary excretion rate of 11-dehydro-
TXB2 was 1263 (955–2006) pg mg
)1 creatinine [median
(IQR)]. Approximately 75% of diabetic patients had 11-
dehydro-TXB2 excretion rates in excess of 2SD above themean
value previously found in non-diabetic subjects using the same
assay [6]. The median urinary excretion rate of 8-iso-PGF2a
was 464 (328–652) pg mg)1 creatinine [median (IQR)]. Fifty
per cent of diabetic patients had 8-iso-PGF2a excretion rates in
excess of 2SD above the mean value previously reported in
non-diabetic subjects [6].
After study drug titration, 94% of the subjects receiving
acarbose had reached the full dose of 100 mg three times daily.
In three patients, the drug was down-titrated to 50 mg twice
daily during the last 4 weeks, owing to gastrointestinal
intolerance. The overall drop-out rate was 11% (two on
acarbose, and four on placebo). The most common reason for
discontinuation was the development of gastrointestinal symp-
toms such as ﬂatulence or diarrhea (Fig. 1). Compliance with
weekly nine-point glucose monitoring was fairly good.
Table 1 shows the demographic and clinical characteristics
of the 48 patients who completed the randomized study. There
were no statistically signiﬁcant differences in any baseline
variable between the two treatment groups (Table 1). Compl-
eters were comparable to non-completers with regard to
baseline characteristics (data not shown).
Body weight, systolic and diastolic blood pressure and lipid
proﬁle were stable throughout the study in both groups (data
not shown).
PPG
The effects of 20 weeks of treatment with acarbose or placebo
on PPG in response to a test meal are illustrated in Fig. 2A,
Screened for eligibility
(n = 139)
Excluded (n = 95)
Presence of exclusion criteria (n = 85)
Refused to partecipate (n = 7)
Other reasons (n = 3)
Randomly assigned to
study drug
(n = 54)
Acarbose group
(n = 27)
Withdrawn (n = 2)
Adverse events (n = 2)
Patient decision (n = 0)
Withdrawn (n = 4)
Adverse events (n = 2)
Patient decision (n = 0)
Placebo group
(n = 27)
Completed
(n = 23)
Completed
(n = 25)
Fig. 1. Study ﬂow diagram.
Postprandial hyperglycemia and platelet activation 831
 2010 International Society on Thrombosis and Haemostasis
and the results of the mixed-effects model repeated measures
analysis are shown in Table S1. The acarbose group had a
signiﬁcantly greater reduction in mean PPG than the placebo
group at weeks 4, 8 and 20. The mean change in PPG levels
after 20 weeks was ) 0.10 log mg dL)1 for the acarbose group
and ) 0.004 log mg dL)1 for the placebo group, giving a
treatment difference of ) 0.098 (95% CI ) 0.15 to
) 0.043) log mg dL)1 (P = 0.001) (Table S1; Fig. S1A).
FPG
The effects of 20 weeks of treatment with acarbose or placebo
on FPG are illustrated in Fig. 2B. The mean change in FPG
levels was signiﬁcantly different between the two treatment
groups after 16 weeks [) 0.036 (95% CI ) 0.067 to
) 0.004) log mg dL)1, P = 0.028], whereas at week 20 the
difference was not signiﬁcant (P = 0.058) (Table S1;
Fig. S1B).
HbA1c
The mean change in HbA1c value was different between the
two treatment groups as early as after 8 weeks (Table S1).
After 20 weeks, the difference between treatments was ) 0.028
(95% CI ) 0.044 to ) 0.011) log percentage points
(P < 0.0001).
MAGE
The effects of 20 weeks of treatment with acarbose or
placebo on MAGE are illustrated in Fig. 2C. The mean
change in glycemic instability as assessed by MAGE was
different between the two treatment groups as early as after
4 weeks, and at each subsequent time point (Table S1). After
20 weeks, the difference between treatments was ) 0.23
(95% CI ) 0.35 to ) 0.11) log mg dL)1 (P < 0.0001) (Ta-
ble S1; Fig. S1C).
HOMA-IR was not affected by either treatment throughout
the study period (Table S1).
Urinary 11-dehydro-TXB2
The intrasubject CV of urinary 11-dehydro-TXB2 excretion
rate averaged 15% ± 7%, as determined on the basis of six
repeated measurements performed in the placebo group
throughout the study.
The mean change in urinary 11-dehydro-TXB2 excretion
rate was signiﬁcantly different between the two treatment
groups as early as after 8 weeks, and at each subsequent time
point. After 20 weeks, the acarbose group had a signiﬁcantly
greater decrease in 11-dehydro-TXB2 levels (by 40% vs.
baseline) than did the placebo group (mean change ) 0.23 vs.
0.031 log pg mg)1 creatinine); the difference between treat-
ments was ) 0.26 (95% CI ) 0.33 to ) 0.18) log pg mg)1
creatinine, P < 0.0001) (Table S1; Fig. 3A).
Plasma P-selectin
The mean change in plasma P-selectin levels was signiﬁcantly
different between the two treatment groups as early as after
8 weeks, and at each subsequent time point. After 20 weeks,
the acarbose group had a signiﬁcantly greater decrease in P-
selectin levels than did the placebo group (mean change ) 0.19
vs. 0.041 log ng mL)1); the difference between treatments was
) 0.23 (95% CI ) 0.33 to ) 0.12) log ng mL)1 (P < 0.0001)
(Table S1; Fig. 3B).
Urinary 8-iso-PGF2a
The intrasubject CV of urinary 8-iso-PGF2a excretion rate
averaged 18% ± 6%. The mean change in urinary 8-iso-
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Fig. 2. Eﬀects of 20 weeks of treatment with acarbose (red line) or pla-
cebo (blue line) on postprandial plasma glucose concentrations in response
to a test meal (A), fasting plasma glucose (B) and mean amplitude of
glycemic excursions (MAGE) (C). Data are represented as
mean ± standard error of the mean.
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PGF2a excretion rate was signiﬁcantly different between the
two treatment groups as early as after 8 weeks, and at each
subsequent time point. After 20 weeks, the acarbose group
had a signiﬁcantly greater (by 33% vs. baseline) decrease in
8-iso-PGF2a excretion rate than did the placebo group (mean
change ) 0.19 vs. 0.013 log pg mg)1 creatinine); the differ-
ence between treatments was ) 0.20 (95% CI ) 0.27 to
) 0.13) log pg mg)1 creatinine (P < 0.0001) (Table S1;
Fig. 3C).
Urinary 8-iso-PGF2a and 11-dehydro-TXB2 excretion rates
were signiﬁcantly related in the placebo group throughout the
study (q 0.41, P < 0.0001). In addition, the percentage of
baseline 8-iso-PGF2a excretion rate was related to the percent-
age of baseline 11-dehydro-TXB2 excretion rate (q 0.58,
P < 0.0001) in the whole group.
Plasma CD40L
The mean change in plasma CD40L levels (intrasubject CV:
35% ± 13%) was not signiﬁcantly different between the two
treatment groups at any time point, except at 16 weeks
(P = 0.015), despite a statistically signiﬁcant median reduction
by 31% vs. baseline after 20 weeks of acarbose (Table S1;
Fig. 3D).
Serum CRP
CRP levels were not affected by either intervention to any
statistically signiﬁcant extent (P = 0.15) (Table S1).
Plasma ADMA
The mean change in plasma ADMA levels (intrasubject CV:
19% ± 10%) was not signiﬁcantly different between the two
treatment groups at any time point (Table S1).
Statistically signiﬁcant correlations were found between
MAGE and 8-iso-PGF2a (q = 0.387, P < 0.0001; Fig. 4A)
over the20-weekacarbose treatmentperiod.PPG,butnotFPG,
was signiﬁcantly related to both 11-dehydro-TXB2 excretion
rate (rho = 0.26, P = 0.001) and 8-iso-PGF2a excretion rate
(q = 0.30, P = 0.0002) during acarbose treatment.
Multiple regression analysis performed by pooling the data
from both treatment groups revealed that urinary 8-iso-PGF2a
excretion rate [standardized regression coefﬁcient (b) = 0.314,
standard error of the mean (SEM) = 0.31, P < 0.0001] and
HbA1c (b = 0.273, SEM = 135.6, P = 0.001) were the only
signiﬁcant predictors of urinary 11-dehydro-TXB2 excretion
rate, independently of acarbose treatment, FPG, PPG,MAGE,
CD40L, P-selectin and ADMA used as covariates. In the 25
Table 1 Baseline characteristics of the 48 type 2 diabetic patients who completed the randomized study, subdivided according to treatment group
Variable Placebo (n = 23) Acarbose (n = 25) P-Value
Male gender, n (%) 12 (52) 14 (56) 0.98
Age (years) 61 (54–65) 62 (51–68) 0.76
BMI (kg m)2) 26.7 (23.7–30.1) 27.0 (24.6–31.2) 0.46
Waist-to-hip ratio 0.96 (0.88–0.99) 0.98 (0.94–1.03) 0.27
Systolic blood pressure (mmHg) 130 (120–146) 130 (120–135) 0.78
Diastolic blood pressure (mmHg) 79 (70–80) 80 (71–87) 0.27
Hypertension, n (%) 13 (56.5) 15 (60) 0.79
Total cholesterol (mg dL)1) 213.9 (173.9–221.9) 191.9 (151.9–225.9) 0.29
HDL cholesterol (mg dL)1) 53.9 (46.9–61.9) 49.9 (43.9–57.9) 0.34
Triglycerides (mg dL)1) 109.1 (91.1–150.2) 108.1 (84.1–152.2) 0.78
Hemoglobin A1c (%) 6.5 (6.1–6.8) 6.7 (6.5–7.0) 0.12
Fasting plasma glucose (mg dL)1) 126.8 (121.8–140.8) 125.87 (115.8–136.8) 0.25
Postprandial plasma glucose (mg dL)1) 160.8 (126.9–180.8) 178.8 (122.9–207.8) 0.49
HOMA-IR 2.66 (2.12–3.46) 2.84 (1.55–4.76) 0.96
MAGE (mg dL)1) 72.3 (46.8–103.1) 81.9 (51.3–101.3) 0.86
Antihypertensives, n (%) 13 (56.5) 15 (60) 0.96
ACE-Is or ARBs, n (%) 10 (43) 12 (48) 0.98
Ca2+ channel blockers, n (%) 5 (21.7) 2 (8) 0.24
b-Blockers, n (%) 1 (4.3) 2 (8) 1.00
Diuretics, n (%) 3 (13) 6 (24) 0.46
Statins, n (%) 4 (17) 8 (32) 0.40
8-iso-PGF2a (pg mg
)1 creatinine) 481 (243–656) 475 (344–664) 0.38
11-dehydro-TXB2 (pg mg
)1 creatinine) 1126 (735–2127) 1509 (1035–2241) 0.43
sCD40L (ng mL)1) 0.61 (0.31–1.72) 0.86 (0.58–1.32) 0.17
P-selectin (ng mL)1) 184 (129–226) 125 (90–200) 0.07
ADMA (lmol L)1) 0.69 (0.58–1.05) 0.76 (0.62–0.85) 0.98
Data are median (interquartile range) unless otherwise speciﬁed. ACE-I, angiotensin-converting enzyme inhibitor; ADMA, asymmetric dime-
thylarginine; ARB, angiotensin receptor blockers; BMI, body mass index, calculated as weight in kilograms divided by the square of the height in
meters; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; MAGE, mean amplitude of glycemic
excursions; PG, prostaglandin; sCD40L, soluble CD40 ligand. SI conversions: to convert total and HDL cholesterol to mmol L)1, divide by 38.6;
to convert triglycerides to mmol L)1, divide by 88.6; to convert glucose to mmol L)1, divide by 18.0.
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patients randomized to acarbose, PPG remained the only
signiﬁcant predictor of urinary 11-dehydro-TXB2 excretion rate
(b = 0.47, SEM = 0.27,P < 0.0001), independently ofFPG,
MAGE, HbA1c and 8-iso-PGF2a excretion rate. In contrast, in
the same group,MAGE (b = 0.42, SEM = 0.83,P = 0.001)
was the only predictor of urinary 8-iso-PGF2a excretion rate,
independently of the other covariates. Among the 16 patients
with 8-iso-PGF2a and 11-dehydro-TXB2 percentage of baseline
in the ﬁrst and second quartiles, 13 (81.2%) had a percentage of
baseline PPG below the median. In contrast, only ﬁve (31%)
patients with 8-iso-PGF2a and 11-dehydro-TXB2 percentage of
baseline in the third and fourth quartiles had a percentage of
baseline PPG below the median (Fig. 4B).
Discussion
In newly detected type 2 diabetes, postprandial but not fasting
glucose is associated with an increased risk of myocardial
infarction and mortality [19].
In the present study, we have demonstrated persistent in vivo
platelet activation and enhanced lipid peroxidation in response
to postprandial hyperglycemic spikes in patients with early
type 2 diabetes mellitus, with HbA1c levels £ 7%, and free of
detectable microvascular and macrovascular complications.
Biochemical evidence of persistent oxidative stress and platelet
activation was obtained from seven repeated measurements
throughout the 23-week study period in patients treated with
placebo. Interestingly, TX biosynthesis was at least as high in
newly diagnosed diabetic patients as previously reported in
patients with longer-standing disease [6], supporting the
hypothesis that platelet activation is related to the metabolic
disorder and not to vascular disease per se [5].
The contribution of postprandial glucose excursions to
overall diurnal hyperglycemia is predominant in well-con-
trolled patients, whereas the contribution of fasting hypergly-
cemia increases with diabetes worsening [20,21]. Because in vivo
lipid peroxidation and platelet activation were downregulated
by a 20-week acarbose treatment, this effect could be largely
attributed to the reduction in postprandial glycemia and acute
glucose ﬂuctuations, as shown by the multiple regression
analyses.
In our study, only PPG (upward glycemic spikes) predicted
thromboxane biosynthesis, consistently with our previous
ﬁnding that acute, short-term hyperglycemia induced by
hyperglycemic clamping enhances urinary 11-dehydro-TXB2
excretion in patients with type 2 diabetes mellitus [22].
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Fig. 3. Mean changes from baseline in urinary 11-dehydro-thromboxane (TX)B2 excretion rate (A), plasma P-selectin (B), urinary 8-iso-prostaglandin
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transformed and represented as least square mean with 95% conﬁdence intervals (CIs).
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The MAGE, which includes both upward (postprandial)
and downward (interprandial) acute ﬂuctuations of glucose
around amean value [9], predicted in vivo lipid peroxidation, as
previously reported by Monnier et al. [9], in a group of 21
patients with type 2 diabetes (mean HbA1c, 9.6%) on oral
antidiabetic drugs.
The statistically signiﬁcant correlation between the urinary
excretion rates of 11-dehydro-TXB2 and 8-iso-PGF2a supports
the hypothesis that persistent platelet activationmay, at least in
part, be related to enhanced formation of biologically active
products of arachidonic acid peroxidation [6], although this
association may simply reﬂect a common trigger of both
phenomena.
Acarbose treatment for 20 weeks induced a time-dependent
reduction of the in vivomarkers of oxidative stress and platelet
activation that followed a progressive improvement of post-
prandial glucose ﬂuctuations and long-term glycemic control.
Thus, both abnormal lipid peroxidation and persistent platelet
activation are reversible, at least in part, by an intervention
aimed at ﬂattening acute glucose ﬂuctuations and PPG, at a
time of the natural history of diabetes when metabolic control
as assessed by HbA1c and FPG is not yet substantially
impaired. Indeed, percentage changes in F2-isoprostane for-
mation and TX biosynthesis were signiﬁcantly related to
MAGE and PPG level changes induced by acarbose.
Reduction of postchallenge hyperglycemia by acarbose has
been shown to prevent acute endothelial dysfunction [10,23],
which prompted us to measure ADMA, an inhibitor of NO
synthase causing reduced NO availability and thus endothelial
dysfunction [24]. The time-dependent pattern of inhibition of
sP-selectin by acarbose, in the face of unaltered levels of
ADMA, is consistent with the hypothesis that the enhanced sP-
selectin in this setting largely originates from platelets rather
than endothelial cells, and may therefore be considered an
additional platelet activation marker. In this regard, our
ﬁndings conﬁrm and extend recent observations reporting
inhibition of soluble selectins as well as platelet-derived
microparticles by acarbose in diabetic patients [25].
CD40L is rapidly upregulated during platelet activation and
promotes further platelet activation [2]. The hypothesis of
CD40L release during TXA2-dependent platelet activation in
type 2 diabetes [26] was conﬁrmed in the present study by the
signiﬁcant reduction in circulating levels of CD40L after
acarbose treatment.
One limitation of the study is that analyses were not
performed on an intention-to-treat basis. However, it should be
emphasized that this was not a therapeutic trial with clinical
endpoints, but rather a mechanistic study with biochemical
endpoints that used acarbose as an investigative tool.
We also acknowledge that assessment of platelet activation
was limited to two in vivo assays. However, it should be
emphasized that measurement of platelet aggregation ex vivo is
merely a capacity index that by nomeans reﬂects the extent and
duration of platelet activation in response to stimuli operating
in vivo.
Moreover, one may argue that, by collecting overnight urine
samples, we evaluated lipid peroxidation and platelet activation
during the fasting state that is characterized by a relative
stability in plasma glucose. This may have weakened the
strength and tightness of the correlations observed between
variables throughout the study.
The simpliﬁcation of the MAGE index determination based
on a 1-day, nine-point glucose proﬁlemay not accurately reﬂect
all of the glucose nadirs and peaks, as compared with the
method previously described [9], using continuous glucose
monitoring over 2 days. However, our aim was to test a
relatively simple, point of care index of glycemic instability in
an early phase of the disease, and evaluate its modulation by
acarbose.
In conclusion, this study provides biochemical evidence of
persistently enhanced lipid peroxidation and platelet activation
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Fig. 4. Relationship between the extent of glycemic instability and lipid
peroxidation and between the changes in PPG levels, lipid peroxidation
and platelet activation throughout the treatment period. (A) Linear rela-
tionship between individual values of mean amplitude of glycemic excur-
sions (MAGE) and urinary 8-iso-prostaglandin (PG)F2a excretion rate
measured in the 25 type 2 diabetic patients who completed the 20-week
randomized treatment with acarbose. Mean ± standard deviation values
of both parameters measured before (square) and after (triangle) acarbose
treatment are also represented. (B) Correlation of individual percentage of
baseline urinary 8-iso-PGF2a and 11-dehydro-thromboxane (TX)B2
excretion rates after the 20-week treatment with placebo (circles) or
acarbose (triangles). Closed symbols represent subjects in the ﬁrst and
second quartiles for percentage of baseline postprandial glycemia. Open
symbols represent subjects in the third and fourth quartiles for percentage
of baseline postprandial glycemia. Vertical and horizontal dotted lines
mark the boundaries of median values of percentage of baseline for both
urinary metabolite excretion.
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in the early phase of the natural history of type 2 diabetes,
characterized by adequate metabolic control, but glucose
ﬂuctuations during postprandial periods, as assessed by
MAGE and PPG. A decrease in PPG and MAGE achieved
with acarbose was associated with downregulation of oxidative
stress and platelet activation in this setting. These ﬁndings may
suggest a causal relationship between early metabolic derange-
ment and persistent platelet activation, thereby providing a
mechanistic explanation for the cardioprotection associated
with acarbose in a meta-analysis of long-term randomized
studies [27].
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